Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Microspheres to Prevent Pancreatic Fistula After Distal Pancreatectomy (Phase III, China)
ChiCTR2600121157Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic fistula (POPF) and Postoperative pancreatic fistula (POPF) comparing Octreotide microspheres arm with Placebo arm (2 arms). Primary endpoint: Incidence of clinically relevant postoperative pancreatic fistula (CR-POPF) at 60 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
octreotide
03
Conditions
pancreatic fistula (POPF)Postoperative pancreatic fistula (POPF)
Beyond the preview
Go deeper on ChiCTR2600121157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121157.